SCHEMBL1095602

SCHEMBL1095602

N#Cc1cccc(S(=O)(=O)Nc2cscn2)c1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GLO1 Q04760 1/20 0.53
SLC40A1 Q9NP59 1/20 0.53
SCN9A Q15858 8/20 0.53
SLC22A12 Q96S37 1/20 0.52
SCN1A P35498 4/20 0.50
SCN5A Q14524 4/20 0.50
SCN8A Q9UQD0 4/20 0.50
NR1I2 O75469 1/20 0.49
SCN1B Q07699 1/20 0.49
PGR P06401 1/20 0.49
ACLY P53396 2/20 0.46
RXFP1 Q9HBX9 1/20 0.46
HSPD1 P10809 1/20 0.44
PTPN2 P17706 1/20 0.44
PTPN1 P18031 1/20 0.44
PTPN5 P54829 1/20 0.44
HSPE1 P61604 1/20 0.44
TRIM24 O15164 1/20 0.44
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22634311 0.80 KMT2A (0.54) SLC40A1SCN9ASCN1ASCN5ASCN8A
SCHEMBL16720161 0.80 SCN1A (0.48) SCN9ASLC22A12SCN1ASCN5ASCN8A
SCHEMBL1093365 0.78 HSD11B1 (0.67) GLO1SLC40A1SLC22A12PGRACLY
SCHEMBL1093569 0.78 GLO1 (0.55) GLO1SLC40A1SCN9ASLC22A12PGR
SCHEMBL1093964 0.78 SCN1A (0.54) SCN9ASCN1ASCN5ASCN8ANR1I2
SCHEMBL19617682 0.76 SCN9A (0.46) SCN9ASLC22A12SCN1ASCN5ASCN8A
SCHEMBL1094074 0.76 SCN9A (0.61) GLO1SLC40A1SCN9ASLC22A12PGR
SCHEMBL1093895 0.75 SLC22A12 (0.69) SLC22A12
SCHEMBL1093536 0.75 GLO1 (0.57) GLO1SLC40A1SCN9APGRACLY
SCHEMBL1094354 0.75 SCN9A (0.52) GLO1SLC40A1SCN9ASLC22A12PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8907101-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2014-12-09 US disclosed
US-20130338111-A1 Sulfonamide Derivatives ICAGEN, INC. (US) 2013-12-19 US disclosed
US-20120149679-A1 Sulfonamide Derivatives ICAGEN, INC. 2012-06-14 US disclosed
US-8153814-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2012-04-10 US disclosed
US-20100197655-A1 SULFONAMIDE DERIVATIVES Pfizer Limited Icagen, Inc. 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197655-A1 SULFONAMIDE DERIVATIVES SULT2A1, SULT1A1, TPST2 GLO1 2222/4885SLC40A1 3958/4885SCN9A 73/4885
US-20130338111-A1 Sulfonamide Derivatives SULT2A1, SULT1A1, TPST2 GLO1 2222/4885SLC40A1 3958/4885SCN9A 73/4885
US-20120149679-A1 Sulfonamide Derivatives SULT2A1, SULT1A1, TPST2 GLO1 2222/4885SLC40A1 3958/4885SCN9A 73/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.